Added Value of Local Clonidine for Spine Postoperative Pain Control, in Addition to Bupivacaine

Sponsor
St Joseph University, Beirut, Lebanon (Other)
Overall Status
Completed
CT.gov ID
NCT01902108
Collaborator
(none)
225
1
2
35
6.4

Study Details

Study Description

Brief Summary

The objective of this prospective randomized double-blind study is to evaluate the added analgesic value of clonidine to the conventional local bupivacaine wound infiltration in posterior spine surgery.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Patients candidates to posterior spine surgery (Micro-discectomy, Lumbar laminectomy with or without fusion, cervical laminectomy) are asked to participate to this prospective study. After verification of inclusion and exclusion criteria, patients consenting to enter the study are randomly assigned to one of the following subgroups: 1-Pre-incisional wound infiltration with 20 mL of bupivacaine 0.25%. 2- Pre-incisional wound infiltration with 150 μg of clonidine with 20 mL of bupivacaine 0.25%. Demographic parameters, co-morbidities and other pre and per operative medical data are noted. In the post-operative period, patients received a standardized post-operative analgesic protocol (NSAI and paracetamol). Patients are asked to fill their pain diary using Visual Analog Scale (VAS) from day 0 till day 8 after surgery. Morphine rescue consumption is noted. Finally, the percentage of global subjective patient satisfaction regarding the post-operative wound pain is noted from 0 to 100.

Study Design

Study Type:
Interventional
Actual Enrollment :
225 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Randomized Double-blind Trial Comparing the Post-operative Analgesic Efficacy of Local Wound Infiltration With Bupivacaine Alone to Bupivacaine With Clonidine in Posterior Spine Surgeries
Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Dec 1, 2015
Actual Study Completion Date :
Dec 1, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Clonidine

Clonidine 150μg added to bupivacaine in a local infiltration before wound incision

Drug: Clonidine
Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision

Active Comparator: Bupivacaine

Bupivacaine 0.25 % alone in the wound infiltration

Drug: Bupivacaine
Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone

Outcome Measures

Primary Outcome Measures

  1. Mean Area under curve [From the day of surgery till the 8th postoperative day (9 days and 8 nights=200h]

    Pain is assessed on numeric rating scale (NRS) 8times/day during the first 3 days, 3times/day during the next 6days and one mean value during the night. The mean intensity of daily pain is obtained from the different values mentioned during day and night corrected by the duration covered by every value. It may vary from 0 to 10.

Secondary Outcome Measures

  1. Area under Curve (AUC) of pain [Calculated at Day 0-2, Day3-5, Day6-8 and all along the follow-up from Day0 till Day8]

    The AUC during an interval (in days) is calculated by adding the different values of pain assessed during day and night multiplied by the duration (in hours) of sufferance from this amount of pain. The AUC during an interval is proportional to the mean intensity of pain suffered during the same interval. It is expressed in pain unit multiplied by hour

  2. Daily rescue opiates consumption [From the day of surgery till the 3rd postoperative day]

    The unit of rescue opiates consumption equals the administration of 5mg of morphine subcutaneously. The minimum interval between 2 rescue opiates consumption is 6 hours. Thus, the rescue opiates consumption may vary from 0 to 4/day.

  3. Global subjective patient satisfaction of post-operative wound pain control [Assessed at the end of follow-up on Day 8]

    It may vary from 0 that means a total dissatisfaction to 100% that means a complete satisfaction

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 72 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • First (not recurrent) posterior spinal surgery at the operated site

  • American Society of Anesthesiologists class I or II (operative risk)

Exclusion Criteria:
  • Allergy to local anesthetics or to clonidine

  • Pregnancy

  • Raynaud's syndrome

  • Thromboangiitis obliterans

  • History of substance abuse

  • Current treatment with corticosteroids

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hotel Dieu de france Hospital Beirut Lebanon 16-6830

Sponsors and Collaborators

  • St Joseph University, Beirut, Lebanon

Investigators

  • Principal Investigator: Joseph Maarrawi, MD, PhD, Laboratory of neurosciences, Faculty of medicine, St Joseph University of Beirut

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Dr Joseph Maarrawi, Assistant Professor : Researcher - Pain Specialist - Neurosurgeon, St Joseph University, Beirut, Lebanon
ClinicalTrials.gov Identifier:
NCT01902108
Other Study ID Numbers:
  • CLON-POBPC
First Posted:
Jul 18, 2013
Last Update Posted:
Dec 8, 2015
Last Verified:
Dec 1, 2015
Keywords provided by Dr Joseph Maarrawi, Assistant Professor : Researcher - Pain Specialist - Neurosurgeon, St Joseph University, Beirut, Lebanon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 8, 2015